ClinicalTrials.gg

Carcinoma, Merkel Cell clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 150 studies for Carcinoma, Merkel Cell across more than 10 countries. 40 are recruiting or about to start. 67 of them are mainly about Carcinoma, Merkel Cell (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-18.

Status

Completed
45
Recruiting
34
Terminated
29
Active, not recruiting
27
Withdrawn
6
Not yet recruiting
5

Phase

Phase 2
83
Phase 1
71
Phase 3
6
Early Phase 1
1

Where

United States
112
Australia
20
France
20
Spain
16
Italy
12
Canada
11

Who develops what

Add Carcinoma, Merkel Cell to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 7 programs from 6 companies, 3 with this as their studies’ main aim; 1 with a live phase 3 study; 1 primary completion in the next 12 months. Compare Novartis, AstraZeneca and Merck here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
pembrolizumabRecent, repeated
Evidence
  • NCT07749586 · Arvinas Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Jul 2026
  • NCT06939036 · Ariceum Therapeutics GmbH · Phase 2 · background · “Pembrolizumab” · registered Apr 2025
  • NCT06947928 · TuHURA Biosciences, Inc. · Phase 3 · live · background · “Pembrolizumab” · registered Apr 2025
  • NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Aug 2023
  • NCT03684785 · Exicure, Inc. · Phase 2 · background · “Pembrolizumab” · registered Sep 2018
Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015)44 studies
NivolumabRecent, repeated
Evidence
  • NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Nivolumab” · registered Aug 2023
  • NCT05267626 · Aulos Bioscience, Inc. · Phase 2 · live · background · “Nivolumab” · registered Feb 2022
  • NCT03435640 · Nektar Therapeutics · Phase 2 · background · “nivolumab” · registered Feb 2018
  • NCT03241173 · Incyte Corporation · Phase 2 · background · “Nivolumab” · registered Aug 2017
  • NCT03228667 · ImmunityBio, Inc. · Phase 2 · live · background · “N-803 + Docetaxel + Nivolumab” · registered Jul 2017
Bristol-Myers Squibb76% of its industry studiesUS: Bristol-Myers Squibb (FDA 2014)EU: Bristol-Myers Squibb (EMA 2015)22 studies
avelumabRecent, repeated
Evidence
  • NCT06939036 · Ariceum Therapeutics GmbH · Phase 2 · background · “Avelumab” · registered Apr 2025
  • NCT05267626 · Aulos Bioscience, Inc. · Phase 2 · live · background · “Avelumab” · registered Feb 2022
  • NCT03853317 · ImmunityBio, Inc. · Phase 2 · background · “Avelumab” · registered Feb 2019
  • NCT03787602 · Ipsen · Phase 2 · live · background · “Avelumab” · registered Dec 2018
  • NCT03167164 · ImmunityBio, Inc. · Phase 2 · background · “Avelumab” · registered May 2017
Pfizer44% of its industry studiesUS: Merck KGaA, Darmstadt, Germany (FDA 2017)EU: Merck KGaA, Darmstadt, Germany (EMA 2017)22 studies

12 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
pDNA-encoding Emm55 Autologous Cancer Cell Vaccine IFx-Hu2.0☆ Track1 live phase-3 study: NCT06947928TuHURA Biosciences, Inc.

The 1 in phase 3 with the nearest primary completion, of 7 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 31 Mar 2027 est.pDNA-encoding Emm55 Autologous Cancer Cell Vaccine IFx-Hu2.0 · TuHURA Biosciences, Inc. · Phase 3 main aimadded to pembrolizumabNCT06947928 Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma — primary endpoint: Objective response rate (ORR) · 118 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Carcinoma, Merkel Cell studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Immune checkpoint inhibitors 10 open · mTOR inhibitors 1 open · Tyrosine kinase inhibitors (TKIs) 5

Coming up

23studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 34 Carcinoma, Merkel Cell studies recruiting now, 27 (79%) set no upper age limit and 0 (0%) stop at 75 or younger. 5 (15%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (3%) take healthy volunteers.

Recruiting studies that take each age, of 34
AgeWomenMen
104 (12%)4 (12%)
1834 (100%)34 (100%)
3034 (100%)34 (100%)
4034 (100%)34 (100%)
5034 (100%)34 (100%)
6534 (100%)34 (100%)
7534 (100%)34 (100%)
8534 (100%)34 (100%)

Across all 150 studies, recruiting or not: 2% stop at 75 or younger and 0% at 65; 5% take children; 0% are for women only and 0% for men only; 3% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Carcinoma, Merkel Cell studies take

Of 33 phase 2 interventional studies under Carcinoma, Merkel Cell, half reached primary completion within 92 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 147 mo36–60 · 25 studies——
Phase 292 mo47–138 · 33 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 150. Browse all 150 → or search them.